Generic Drugs Will Be More Expensive For CKD, Dialysis & Kidney Transplant Patients Without Your Action



"More than  80% of the drugs we take in the United States are now generic versions of brand name medications," according to Doctor Oz. Due to high costs of brand names, generic drugs are important options that allow greater access to Healthcare for all Chronic Kidney Disease, Dialysis and Kidney Transplant patients. Well, new reports of a major merger of two leading Drug Manufactures could ultimately drive up consumers’ costs.

Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company which specializes primarily in generic drugs. The company is well known for the commonly used Kidney Transplant Immunosuppressant Drug, Mycophenolate mofeti, as well as the ACE Inhibitor, Perindopril (used primarily for the treatment of hypertension and congestive heart failure). Recently announced plans for Teva to purchase another leading generic drug developer, Allergan Generics, may be bad news for Chronic Kidney Disease, Dialysis and Kidney Transplant patients.

Recommended Reading: Truth About Generic V.S. Brand Name Drugs & How They Impact Chronic Kidney Disease Patients' Health

Consumer Watchdog Organizations such as Consumers Union and the National Center for Health Research have suggested that, "An even more concentrated generic drug market would likely result in both unilateral and coordinated anticompetitive effects, including further price increases and a diminished competitive drive within the industry to develop new generic drugs." The low margins and growing popularity of generic drugs have pharmaceutical companies seeking out ways to drive up profits. 

Recommended Reading: Prices of Immunosuppressants have Substantially Decreased, Why are They Still So Expensive?

If prices were to increase on necessary drugs, it could jeopardize Kidney Transplant Recipients' ability to afford vital Immunosuppressant Medications. Also, if Dialysis patients cannot afford life preserving medications then they too may be at risk of serious and life-threatening implications. Hence, we as a Chronic Kidney Disease Community must stand together. Sign the below petition which will be sent to the Federal Trade Commission in protest of this proposed acquisition.

Recommended Reading: New Study: Are 20 Doses A Day Too Much Of A Burden Or Just Right For CKD Patients?

Earlier in the year, opponents to a similar merger joined together and Teva abandoned the deal. Sign the petition and pass it along to Friends and Family for further support. 

Recommended Reading: Drugs Often Prescribed To Chronic Kidney Disease Patients On Dialysis Found To Be High In Phosphorus 

For the Latest Breaking News in the Chronic Kidney Disease Community which teaches those with Chronic Kidney Disease, Dialysis, Diabetes and Hypertension how to better manage and improve their lives, visit every day. Also, Like the Facebook Fan Page to have access to real-time peer-to-peer conversation with over 25,300 Friends (click here).

Sign Petition

Name *
Phone *

Most Popular Stories: